Get the Stockscreener App
23.48
48.69%
-22.01
Agios Pharmaceuticals Inc stock is traded at $23.48, with a volume of 13.53M.
It is down -48.69% in the last 24 hours and down -44.86% over the past month.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
See More
Previous Close:
$45.49
Open:
$23.29
24h Volume:
13.53M
Relative Volume:
16.21
Market Cap:
$2.65B
Revenue:
$32.87M
Net Income/Loss:
$674.31M
P/E Ratio:
2.0668
EPS:
11.36
Net Cash Flow:
$-330.11M
1W Performance:
-46.50%
1M Performance:
-44.86%
6M Performance:
-21.78%
1Y Performance:
-57.10%
1-Day Range:
$22.35
$25.07
1-Week Range:
$22.35
$46.00
52-Week Range:
$22.35
$62.45
Agios Pharmaceuticals Inc Stock (AGIO) Company Profile
Name
Agios Pharmaceuticals Inc
Sector
Industry
Phone
617-649-8600
Address
88 SIDNEY STREET, CAMBRIDGE, MA
Compare AGIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AGIO
Agios Pharmaceuticals Inc
|
23.45 | 2.65B | 32.87M | 674.31M | -330.11M | 11.36 |
|
ARGX
Argen X Se Adr
|
917.15 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
202.50 | 43.00B | 447.02M | -1.18B | -906.14M | -6.1812 |
|
VRTX
Vertex Pharmaceuticals Inc
|
420.70 | 110.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
ONC
Beone Medicines Ltd Adr
|
356.02 | 40.27B | 4.98B | 69.59M | 525.67M | 0.5197 |
|
REGN
Regeneron Pharmaceuticals Inc
|
705.05 | 76.23B | 14.25B | 4.58B | 3.88B | 41.77 |
Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-24-25 | Initiated | H.C. Wainwright | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Sep-27-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Feb-08-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-03-23 | Initiated | Piper Sandler | Overweight |
| Nov-17-22 | Upgrade | Goldman | Sell → Neutral |
| Jul-27-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Dec-03-21 | Initiated | BofA Securities | Buy |
| Jul-30-21 | Downgrade | Goldman | Neutral → Sell |
| Jul-01-21 | Initiated | Raymond James | Mkt Perform |
| Jun-10-21 | Initiated | H.C. Wainwright | Buy |
| Mar-01-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Mar-01-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Feb-26-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Oct-22-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-04-20 | Initiated | Barclays | Equal Weight |
| Nov-26-19 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
| May-23-19 | Resumed | Goldman | Neutral |
| Feb-15-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-25-18 | Initiated | Leerink Partners | Mkt Perform |
| May-23-18 | Initiated | Citigroup | Buy |
| Apr-11-18 | Reiterated | Credit Suisse | Outperform |
| Feb-15-18 | Reiterated | Needham | Buy |
| Feb-15-18 | Reiterated | SunTrust | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Aug-10-17 | Reiterated | Needham | Buy |
| Aug-08-17 | Reiterated | SunTrust | Buy |
| Aug-02-17 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| Jun-26-17 | Downgrade | Janney | Buy → Neutral |
| Jan-17-17 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-24-16 | Initiated | Needham | Buy |
| Jun-13-16 | Upgrade | JP Morgan | Neutral → Overweight |
| May-18-16 | Reiterated | SunTrust | Buy |
View All
Agios Pharmaceuticals Inc Stock (AGIO) Latest News
Agios Pharmaceuticals (AGIO) Faces Uncertainty After Trial Resul - GuruFocus
Agios Pharmaceuticals (AGIO) Sees Sharp Decline in Stock Price - GuruFocus
Agios shares fall on mixed sickle cell results for blood disease drug - BioPharma Dive
Why Is Agios Pharmaceuticals Stock Sinking Today? - Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Agios (AGIO) Phase 3 RISE UP Trial Results: Key Insights - GuruFocus
Agios shares tumble on mixed results for sickle cell drug trial - MarketScreener
Agios (AGIO) Trial Results Impact Market Dynamics - GuruFocus
A Sickle Cell Trial Delivers Mixed Results. Agios Stock Falls by 48%. - Barron's
Agios Pharmaceuticals (AGIO) Shares Plummet by Over 47% - GuruFocus
Agios Pharm stock hits 52-week low at $23.23 By Investing.com - Investing.com Nigeria
Agios Pharmaceuticals (AGIO): Assessing Current Valuation After Strong Revenue Growth and Improved Net Income - Yahoo Finance
Agios Pharmaceuticals (AGIO) Shares Plummet After Mixed Trial Re - GuruFocus
AGIO Stock Cracks After Sickle-Cell Disease Drug Delivers Mixed Results In Late-Stage Trial - MSN
Agios falls after mixed data from late-stage trial for sickle cell therapy - Seeking Alpha
Agios reports mixed results in sickle cell disease trial of mitapivat - Investing.com Australia
Agios Pharmaceuticals (AGIO) Reports Promising Phase 3 Trial Res - GuruFocus
Agios announces topline results from Rise Up phase 3 trial of Mitapivat in sickle cell disease - MarketScreener
Is Agios Pharmaceuticals Inc. (8AP) stock a top dividend aristocrat candidateQuarterly Portfolio Review & Long-Term Safe Investment Plans - newser.com
Agios Pharmaceuticals Reports Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease, Meeting Primary Endpoint of Hemoglobin Response - Quiver Quantitative
Agios Pharmaceuticals stock tumbles after mixed sickle cell trial results By Investing.com - Investing.com India
Agios Pharmaceuticals stock tumbles after mixed sickle cell trial results - Investing.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Agios (Nasdaq: AGIO) Shares Phase 3 Mitapivat Sickle Cell Data, Eyes 2026 U.S. Filing - Stock Titan
Will Agios Pharmaceuticals Inc. (8AP) stock hit analyst forecastsQuarterly Profit Summary & Expert Verified Movement Alerts - newser.com
Published on: 2025-11-19 02:41:50 - newser.com
How supply chain issues affect Agios Pharmaceuticals Inc. stockM&A Rumor & Short-Term High Return Strategies - newser.com
Will Agios Pharmaceuticals Inc. (8AP) stock beat growth indexes2025 Breakouts & Breakdowns & Smart Allocation Stock Tips - newser.com
Published on: 2025-11-19 03:33:45 - newser.com
What earnings revisions data tells us about Agios Pharmaceuticals Inc.Market Rally & High Yield Equity Trading Tips - newser.com
Will Agios Pharmaceuticals Inc. benefit from macro trendsPortfolio Value Summary & Growth Oriented Trade Recommendations - newser.com
How Agios Pharmaceuticals Inc. (8AP) stock moves on employment dataTrade Ideas & Long Hold Capital Preservation Tips - newser.com
Is it time to cut losses on Agios Pharmaceuticals Inc.2025 Year in Review & Real-Time Buy Zone Alerts - newser.com
Is Agios Pharmaceuticals Inc 8AP a good long term investmentSupport and Resistance Levels & Create Passive Income With Smart Stocks - earlytimes.in
Can Agios Pharmaceuticals Inc. stock reach $100 price targetWeekly Profit Analysis & AI Based Trade Execution Alerts - newser.com
Will Agios Pharmaceuticals Inc. stock see PE expansionJuly 2025 Recap & Free Fast Gain Swing Trade Alerts - newser.com
(AGIO) Movement as an Input in Quant Signal Sets - news.stocktradersdaily.com
How Agios Pharmaceuticals Inc. (8AP) stock correlates with oil markets2025 Sector Review & Consistent Profit Trading Strategies - newser.com
Institutional scanner results for Agios Pharmaceuticals Inc.July 2025 Pullbacks & Weekly High Potential Stock Alerts - newser.com
Is Agios Pharmaceuticals Inc. building a consolidation baseQuarterly Earnings Summary & Capital Efficient Trading Techniques - newser.com
Is Agios Pharmaceuticals Inc. stock supported by strong cash flowsWeekly Trading Summary & Expert Verified Movement Alerts - newser.com
Published on: 2025-11-14 14:27:10 - newser.com
Agios Pharmaceuticals Inc Stock (AGIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Agios Pharmaceuticals Inc Stock (AGIO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Scadden David | Director |
Nov 12 '25 |
Sale |
43.84 |
200 |
8,768 |
17,603 |
| Gheuens Sarah | Chief Medical Officer |
Nov 11 '25 |
Option Exercise |
25.01 |
2,454 |
61,375 |
64,181 |
| Gheuens Sarah | Chief Medical Officer |
Nov 11 '25 |
Sale |
43.78 |
2,454 |
107,436 |
61,727 |
0.01%
1.36%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):